STOCKHOLM (Reuters) – Rival anti-clotting drugs from Bayer (BAYGn.DE) and Bristol-Myers Squibb (BMY.N) both impressed in clinical trials, keeping them firmly in the race to displace the old, problematic heart drug warfarin.
via news.yahoo.com
« July 2010 | Main | September 2010 »